Piramal Pharma Limited has informed the Exchange about Investor Presentation
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Piramal Pharma reported FY26 revenue of ₹8,869 Cr, down 3% YoY from ₹9,151 Cr in FY25, impacted by inventory destocking, slower early-stage CDMO order inflows in H1, and softer ex-US inhalation anesthesia traction. Adjusted for destocking, the company delivered growth in Q4. EBITDA fell 28% to ₹1,135 Cr with margin contracting to 13% from 17% in FY25, partly offset by cost optimization. A ₹176 Cr impairment on intangible assets under development drove a net loss of ₹326 Cr for FY26 (vs. profit of ₹91 Cr in FY25). CDMO revenue dropped 10% to ₹4,915 Cr while Consumer Healthcare grew 17% to ₹1,274 Cr. The company completed the Kenalog® acquisition (US$35 Mn upfront + up to US$65 Mn contingent) and maintained its US sevoflurane leadership with 47% market share. Management flagged FY26 as transitional and expects FY27 growth driven by improving biopharma funding, CDMO order momentum, and the Kenalog launch.
FY26 was a challenging year with margin compression and a net loss due to impairment charges. The stock may face near-term pressure, but management's upbeat FY27 outlook—backed by CDMO order inflow recovery, US Capex ramp-up, and the Kenalog acquisition—could support a recovery if execution improves.